This licensing deal will see Sanofi leverage the LinearDesign platform that will lead to the optimisation of mRNA sequences for human therapeutic and preventive uses. Furthermore, this agreement
The expanded EUA allows the administration of booster dose to individuals of 18 years of age and older who have received primary dosages. With the same dosage strength
Danish pharma company Novo Nordisk has agreed to acquire Dicerna Pharmaceuticals and its ribonucleic acid interference (RNAi) platform in a deal valued at $3.3bn, to expand the RNAi
Pfizer has secured a contract worth $5.29bn from the US government to supply its experimental Covid-19 oral antiviral drug, Paxlovid (PF-07321332; ritonavir). Designed to hinder the SARS-CoV-2-3CL protease
GlaxoSmithKline (GSK) and Vir Biotechnology have secured contracts from the US government for nearly $1bn to supply their Covid-19 antibody treatment, sotrovimab. Sotrovimab is an investigational single-dose SARS-CoV-2
Pfizer has completed the acquisition of all outstanding shares of clinical-stage immuno-oncology firm Trillium Therapeutics in a deal worth about $2.22bn, or $18.50 per share, in cash. The
Acelyrin has raised $250m through the series B financing round to license and acquire other programmes with focus on immunology. The funding round was led by Matrix Capital
Pfizer has submitted an application to the US Food and Drug Administration (FDA) for Emergency Use Authorisation (EUA) of its investigational oral antiviral drug, Paxlovid (PF-07321332; ritonavir). Paxlovid
Health Canada has authorised the booster shot of Moderna’s Covid-19 vaccine, Spikevax, for individuals aged 18 years and above. The 50µg booster shot will be given at least
The European Commission (EC) has granted marketing authorisation for Roche’s Ronapreve to treat non-hospitalised Covid-19 patients aged 12 years and above. Ronapreve is a combination of monoclonal antibodies,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.